Functional Evaluations of Genes Disrupted in Patients with Tourette’s Disorder by Nawei Sun et al.
February 2016 | Volume 7 | Article 111
Review
published: 09 February 2016
doi: 10.3389/fpsyt.2016.00011
Frontiers in Psychiatry | www.frontiersin.org
Edited by: 
Peristera Paschou, 
Democritus University of Thrace, 
Greece
Reviewed by: 
Fotis Tsetsos, 
Democritus University of Thrace, 
Greece 
Marianthi Georgitsi, 
Aristotle University of Thessaloniki, 
Greece
*Correspondence:
Gary A. Heiman  
heiman@dls.rutgers.edu
Specialty section: 
This article was submitted to Child 
and Adolescent Psychiatry, 
a section of the journal 
Frontiers in Psychiatry
Received: 14 December 2015
Accepted: 18 January 2016
Published: 09 February 2016
Citation: 
Sun N, Tischfield JA, King RA and 
Heiman GA (2016) Functional 
Evaluations of Genes Disrupted in 
Patients with Tourette’s Disorder. 
Front. Psychiatry 7:11. 
doi: 10.3389/fpsyt.2016.00011
Functional evaluations of Genes 
Disrupted in Patients with 
Tourette’s Disorder
Nawei Sun1,2 , Jay A. Tischfield1,2 , Robert A. King3 and Gary A. Heiman1,2*
1 Department of Genetics, Rutgers University, Piscataway, NJ, USA, 2 Human Genetics Institute of New Jersey, Piscataway, 
NJ, USA, 3 Child Study Center, Yale School of Medicine, New Haven, CT, USA
Tourette’s disorder (TD) is a highly heritable neurodevelopmental disorder with complex 
genetic architecture and unclear neuropathology. Disruptions of particular genes have 
been identified in subsets of TD patients. However, none of the findings have been rep-
licated, probably due to the complex and heterogeneous genetic architecture of TD that 
involves both common and rare variants. To understand the etiology of TD, functional 
analyses are required to characterize the molecular and cellular consequences caused 
by mutations in candidate genes. Such molecular and cellular alterations may converge 
into common biological pathways underlying the heterogeneous genetic etiology of TD 
patients. Herein, we review specific genes implicated in TD etiology, discuss the func-
tions of these genes in the mammalian central nervous system and the corresponding 
behavioral anomalies exhibited in animal models, and importantly, review functional 
analyses that can be performed to evaluate the role(s) that the genetic disruptions might 
play in TD. Specifically, the functional assays include novel cell culture systems, genome 
editing techniques, bioinformatics approaches, transcriptomic analyses, and genetically 
modified animal models applied or developed to study genes associated with TD or 
with other neurodevelopmental and neuropsychiatric disorders. By describing methods 
used to study diseases with genetic architecture similar to TD, we hope to develop a 
systematic framework for investigating the etiology of TD and related disorders.
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iNTRODUCTiON
Tourette’s Disorder (TD) is a childhood-onset neurodevelopment disorder characterized by the 
presence of both motor and vocal tics. Prevalence ranges from 1–3% and is found across many 
ethnic groups around the world (1). However, a recent meta-analysis of previous TD prevalence 
studies re-estimates the population prevalence of TD to be 0.3–0.9% (2). Males are affected three to 
four times more often than females (3–5). A high percentage of TD patients have comorbid condi-
tions, most commonly attention-deficit/hyperactivity disorder (ADHD) and obsessive–compulsive 
disorder (OCD) and to a lesser extent autism spectrum disorders (ASDs).
Consistent evidence from family and twin studies suggest a significant genetic contribution to 
TD, most likely the result of complex and heterogeneous inheritance involving both common and 
rare variants, though most of specific findings still require replication. The neurobiological basis of 
TD is not well understood, but appears to involve alterations in the development, structure, and/or 
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functioning of cortico-striato-thalamo-cortical (CSTC) circuits 
(6). Specific genes have been found to be associated with TD. It 
is unclear if mutations in these genes cause TD and, if so, how 
these alterations affect the function or structural development of 
the nervous system. Our focus is to review the neurobiology of 
TD, describe the biological functions of those genes previously 
associated with TD, and discuss the various functional analyses 
that are required for evaluating and establishing the pathogenic-
ity of these putative genetic causal variants for TD.
NeUROBiOLOGY OF TOUReTTe’S 
DiSORDeR
Alterations of the CSTC circuits are considered as the neu-
ropathological basis of tic generation (6, 7). These alterations 
are apparent in functional and structural imaging studies (8), 
histopathological studies of specific neuronal populations (9), 
and defective inhibition in various electroneurophysiological 
experimental paradigms (10, 11). In addition to the male pre-
dominance, the developmental features of TD pose an explana-
tory challenge, with tics usually not appearing till 4–6 years of 
age and most often, but not always, improving spontaneously by 
late adolescence.
Neurotransmitter pathways that modulate the activity and 
the output of the CSTC circuits in the basal ganglia have been 
the focus of intensive investigation, driven in part by the quest 
for more effective pharmacological interventions. The most 
supported neurotransmitter dysregulation hypothesis in TD 
involves the hyperactivity or imbalance of the dopamine signal-
ing in the striatum (12). Within the basal ganglia, dopamine is 
released to the striatum by dopaminergic neurons originating 
from the substantia nigra. In the striatum, the effect of dopamine 
on subsequent neural signal transmission is modulated by the 
striatal medium spiny neurons expressing either D1 or D2-like 
dopamine receptors (13). The dopamine hypothesis is supported 
by the clinical observation that dopamine D2 receptor antago-
nists effectively reduced tics in some TD patients (14, 15). Also, 
dopamine pathway dysregulation was reported in post-mortem 
TD brain samples (16, 17) and in living TD patients’ brain (12, 
18).
Due to their excitatory and inhibitory effects within CSTC 
circuits, glutamatergic and GABAergic pathways have also been 
studied in TD. In post-mortem samples, lower levels of glutamate 
in subcortical brain regions were reported (19). However, it is 
unclear whether TD is associated with hyper- or hypo-glutamate 
levels (20). For the GABAergic pathway, an altered number and 
distribution of striatal GABAergic neurons were described in TD 
post-mortem brain samples (9, 21).
Disrupted serotonin signaling has been implicated in OCD, a 
common comorbid condition among TD patients. Selective sero-
tonin reuptake inhibitors (SSRIs) have proven effective in reduc-
ing OCD symptoms (22) and are also used to treat TD patients 
with comorbid OCD (23). Interestingly, sequence variants at the 
serotonin transporter (SERT) gene were found in both OCD and 
TD patients (24), suggesting alterations in the serotonin pathway 
as one possible mechanism in the etiology of TD.
Until the recent discovery of a dominant negative non-sense 
mutation in the HDC gene co-segregating with TD in a large family, 
histaminergic (HA) neurotransmission was not considered a top 
candidate for TD etiology (25). However, other findings provide 
additional support for the involvement of HA neurotransmission 
in TD. For example, single nucleotide polymorphisms (SNPs) 
within the HDC gene region showed association with TD (26). 
Also, rare copy number variants (CNVs) found in TD patients 
were enriched in chromosomal regions harboring HA pathway 
genes (27). Furthermore, mice lacking the Hdc gene exhibited 
tic-like behaviors (28). Even though no evidence showed direct 
actions of serotonin and histamine on movements, it is proposed 
that serotonin and histamine pathways might indirectly regulate 
movements by modulating the dopamine system in the substan-
tia nigra. In particular, both serotoninergic and HA innervations 
are observed in the substantia nigra (29, 30). Also, serotonin and 
histamine receptors are expressed on nigrostriatal dopaminergic 
neurons (30, 31).
Aside from the neurotransmitter dysregulation hypothesis in 
TD, developmental and neuroimmunological findings also pro-
vide a context for assessing the relevance of potential gene find-
ings. Altered distribution of parvalbumin interneurons (21) and 
reduced numbers of parvalbumin and cholinergic interneurons 
in basal ganglia were observed in the post-mortem brain samples 
of TD patients (9), suggesting another possible, perhaps develop-
mental, mechanism for alterations of CSTS circuits. Additionally, 
a dysregulated brain-immune system involving microglia cells 
was suggested to contribute to TD (32). Gene expressions of 
inflammatory factors were examined using post-mortem basal 
ganglia samples from TD patients and controls (33). An elevated 
expression of the CD45 gene was observed in TD patients even 
though the elevation was not statistically significant. CD45 is a 
surface marker of microglia and its expression is increased due 
to the activation of microglia. In another study, transcriptome 
analysis of post-mortem striatum of TD patients and controls 
revealed upregulation of microglia-related genes (34).
GeNeS DiSRUPTeD iN PATieNTS wiTH 
TOUReTTe’S DiSORDeR
In this section, we will review 15 genes that have been associated 
in TD (Table 1); to suggest how we might move beyond asso-
ciation to establish a role in TD pathogenesis, we will examine 
what is known about the biological effects of these genes. We 
group these genes into several categories: (1) neurite outgrowth: 
SLITRK1; (2) histamine pathway: HDC; (3) serotonin pathway: 
SERT, HTR1A HTR2B; (4) glutamate pathway: SLC1A3; (5) 
synaptic signal transduction and cell-adhesion pathway: NLGN4, 
CDH2, CNTNAP2/CASPR2, DPP6; (6) mitochondrial functions: 
IMMP2L, MRPL3; and (7) genes associated with other diseases: 
DNAJC13 [Parkinson’s disease (PD)], OFCC1 (orofacial clefts), 
and HCRTR2 or OX2R (excessive daytime sleepiness). The diverse 
functions of these genes – ranging from neurotransmitter syn-
thesis, neuronal migration, synaptic plasticity, cell adhesion, and 
protein transportation and synthesis – highlight the complexity 
of unraveling the pathogenesis of TD. However, in addition to the 
TABLe 1 | Genes disrupted in TD.
Biological 
pathways
Gene name Disruption(s) found in TD 
patients and references
Neurite outgrowth SLITRK1 Inversion, frameshift variant, 
Var321 (38)
Synonymous variant: 708C > T (39)
3’-UTR variant: 3383G > A (43)
3225 T > C (41)
D397G (44)
Histamine HDC W317X (25)
Intronic transition and synonymous 
variants: 426C > A, 1743G > A (55)
Serotonin SERT I425V and 5-HTTLPR (24)
HTR1A R219L (78)
HTR2B M63R, R449Q (79)
Glutamate SLC1A3/EAAT1 E219D (88)
Synaptic signal 
transduction and 
cell adhesion
NLGN4/NLGN4X Deletion across exon 4, 5 and 
6 (99)
CDH2 N706S, N845S (106)
CNTNAP2 Intronic insertion (121)
DPP6 Microdeletion at exon 1 (128)
Mitochondrial  
functions
IMMP2L Translocation (141)
De novo duplication (142)
Translocation and cryptic deletion 
eliminated the exon 1–3 (143)
Intragenic deletions (144)
MRPL3 S75N (150)
Genes associated 
with other diseases
DNAJC13 
(Parkinson’s disease)
A2057S (150)
OFCC1 (orofacial 
clefts)
R129G and a novel variant at 
5′-UTR (150)
HCRTR2/OX2R 
(excessive daytime 
sleepiness)
P10S (162)
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genetic disruptions discussed here, large structural variations, for 
example copy number variations (CNVs), have also been investi-
gated in TD patients. Genes disrupted by these structural variants 
have been discovered and indicated as potential TD associated 
genes (35–37).
Neurite Outgrowth
SLIT and NTRK-Like Family, Member 1 (SLITRK1)
In a TD patient with comorbid ADHD, a de novo chromosome 
13 inversion was identified (38). The SLITRK1 gene was mapped 
close to the breakpoints. Targeted sequencing of the SLITRK1 
gene identified a non-coding variant (var321) and a frameshift 
mutation (38) in another 174 unrelated TD patients but not in 
a large control sample. The frameshift mutation led to impaired 
dendrite growth in neurons and the var321 variant may cause 
reduced SLITRK1 protein expression (38). While the var321 and 
additional novel variants within SLITRK1 were found in other 
TD patients, these associations were not replicated in subsequent 
studies (39–49).
Members of the SLITRK protein family are transmembrane 
proteins. They are structurally homologous to the SLIT and the 
TRK proteins, which are involved in axon guidance pathway and 
neurodevelopment (50). The SLITRK1 gene is highly expressed 
in developing and mature neuronal tissues and promotes neurite 
outgrowth in culture (51). The SLITRK1 protein is localized to 
the post-synaptic densities and has been hypothesized to affect 
synapse formation at excitatory synapses through interactions 
with the pre-synaptic cellular adhesion molecule LAR-RPTP (52, 
53). In Slitrk1 knockout mice, although stereotypic behaviors 
were not observed, the mice exhibited anxiety-like and depres-
sion-like behaviors, which were attenuated by chemicals modu-
lating noradrenergic neurotransmission (54). Neurochemical 
abnormalities were also detected in Slitrk1 knockout mice: 
norepinephrine and its metabolites were significantly increased 
in the prefrontal cortex and the nucleus accumbens while choline 
and acetylcholine levels were significantly lower in the striatum 
(54). Taken together, the evidence suggests that the SLITRK1 gene 
might play a role in neurochemical modulation.
Histamine Pathway
Histidine Decarboxylase
Histamine neurotransmission was first linked to the etiology of 
TD when a rare non-sense mutation within the HDC gene was 
discovered in a multiplex family in which the father and all eight 
children were diagnosed with TD. The mutation resulted from a 
G to A transition at the ninth exon of the HDC gene and led to a 
premature stop codon (W317X) (25). The heterozygous W317X 
mutation co-segregated with all affected individuals in this family. 
The W317X mutation was not found in 3360 unrelated individu-
als unaffected with TD or another 720 TD patients, suggesting 
this is a very rare cause for TD. In vitro enzymatic assay dem-
onstrated that the truncated protein produced by the mutation 
lost histidine decarboxylase (HDC) activity and had a dominant 
negative effect on the activity of wild-type HDC protein. After 
the initial finding, more TD patients were screened for mutations 
in the HDC gene in different studies. Only an intronic variant 
and two synonymous variants were identified in a study involving 
120 TD patients (55). However, an association of the HDC gene 
and TD phenotypes was reported in a study including 520 TD 
nuclear families (26). Also, rare, genic CNVs identified in 460 TD 
patients were enriched for HA pathway genes (27), supporting the 
potential involvement of the histamine pathway in TD etiology.
In the adult human central nervous system, the HDC gene is 
exclusively expressed in the soma and axon varicosities of HA 
neurons mostly originating from the tuberomammillary nucleus 
in the posterior hypothalamic region of the brain (30). The HDC 
homodimer converts l-histidine into histamine in the soma of 
HA neurons. Histamine-containing neuronal fibers are seen 
in many brain areas in rodents and human including cerebral 
cortex (56, 57). Therefore, loss-of-function mutations at the 
HDC gene will likely cause a lack of histamine in the widespread 
brain regions receiving HA innervation. In addition to serving 
as a neurotransmitter, histamine is a neuromodulator, inhibiting 
dopamine release by striatal dopaminergic neurons through 
binding to the H3 receptors expressed on these neurons in mice 
(58). Given the hypothesis that hyperactivity of nigrostriatal 
dopaminergic neurons is responsible for tic generation (12), it is 
reasonable that histamine dysregulation may contribute to TD.
Since HDC protein functions as a homodimer (59), indi-
viduals harboring the W317X mutation have approximately 
25% residual HDC activity remaining compared to the healthy 
February 2016 | Volume 7 | Article 114
Sun et al. Functional Studies in Tourette’s Disorder
Frontiers in Psychiatry | www.frontiersin.org
controls. Therefore, the Hdc knockout mice may recapitulate the 
behavioral outcomes caused by the W317X mutation in humans. 
As expected, the Hdc knockout mice show tic-like stereotypic 
behaviors after psychostimulant administration and reduced pre-
pulse inhibition (28). Interestingly, the striatal dopamine level 
was increased in the Hdc knockout mice during the dark cycle, 
which could be decreased by administration of histamine in the 
knockout mice. Also, higher levels of dopamine D2 receptor 
occupancy were found in the basal ganglia of TD patients carry-
ing the W317X mutations, the Hdc knockout mice and the Hdc 
heterozygous mice, indicating that the dopamine release in the 
basal ganglia of the brain might be disinhibited due to histamine 
depletion (28). Taken together, parallel studies in TD subjects and 
mice demonstrated that lack of histamine results in dopamine 
dysregulation, providing a potential mechanism for the proposed 
role of dopamine disruption in TD (12).
Serotonin Pathway
Serotonin Transporter (SLC6A4 or SERT)
Given the effectiveness of the SSRIs in reducing OCD symptoms, 
the SERT gene has been studied as candidate gene for OCD 
(60–64). Serotonin-transporter-linked polymorphic region 
(5-HTTLPR) polymorphisms and a gain-of-function missense 
mutation I425V have been associated with OCD (65–69). 
Sequence variants of the SERT gene were first associated with TD 
in a two-generation pedigree (24). In this family, the heterozy-
gous “long” 5-HTTLPR variant and the I425V mutation perfectly 
segregated with TD individuals in a dominant pattern. The “long” 
5-HTTLPR produces higher SERT mRNA level compared to the 
“short” 5-HTTLPR (70). The I425V mutation results in constitu-
tive activation of the SERT protein whose activity is regulated by 
cGMP-dependent protein kinase (71). Therefore, carrying both 
“long” 5-HTTLPR and the I425V mutation is expected to have 
a synergistic effect that increases the expression of SERT mRNA 
and increases the amount of activated SERT protein.
In the mammalian central nervous system, the SERT gene is 
primarily expressed in the serotonergic neurons that originate 
from the raphe nucleus in the hindbrain and project widely to 
other parts of the nervous system, descending to the spinal cord 
and ascending to the forebrain (72). The human SERT protein is a 
transmembrane protein (73, 74). Cell surface expression of SERT 
protein can be regulated by SERT antagonists and substrates 
(75). The serotonergic axons can innervate and regulate other 
neurotransmission systems. For example, serotonin can facilitate 
or inhibit dopamine release in the striatum in a direct or indirect 
manner (76). Therefore, dysregulation of SERT expression on the 
plasma membrane may affect dopamine transmission (77). So far, 
no other sequence variants in the SERT gene have been associated 
with TD and no corresponding transgenic mice are available for 
in vivo studies.
Serotonin Receptor 1A (HTR1A) and Serotonin 
Receptor 2B (HTR2B)
In addition to the SERT gene, other serotonin pathway genes have 
been examined in TD patients. A missense mutation causing an 
amino acid change from arginine to leucine was identified in the 
serotonin receptor 1A gene (HTR1A) in one TD patient. However, 
the mutation was not predicted to change the receptor activity 
(78). Two novel non-synonymous missense variants and three 
known SNPs in the serotonin receptor 2B (HTR2B) gene were 
also found in 132 Caucasian and 128 Chinese Han TD individu-
als, though the associations were not statistically significant (79).
There are currently 14 known serotonin receptors and these are 
categorized into seven classes (80, 81). The HTR1A and HTR2B, 
both of which are G protein-coupled receptors, belong to class 
I and class II, respectively (81). The HTR1A receptor is highly 
expressed in the brain. Lower brain expression of the HTR1A 
receptor has been associated with mood disorders in humans. 
Htr1a knockout mice exhibit depression- and anxiety-like behav-
iors and have been used for antidepressant drug screening (82, 
83). The HTR1A receptors are located at both pre-synaptic and 
post-synaptic neurons in the CNS. Activation of the pre-synaptic 
HTR1A receptors on the serotonergic neurons leads to inhibi-
tion of serotonergic neuron firing and reduced serotonin release 
whereas activation of the post-synaptic HTR1A can modulate the 
release of other neurotransmitters (84). Compared to the HTR1A 
receptor, the role that HTR2B plays in the CNS is not well under-
stood. However, there is evidence suggesting that HTR2B may 
regulate SERT activity by phosphorylating SERT protein (85). In 
mice, the HTR2B receptor may be involved in modulating sero-
tonin release from the serotonergic neurons. (86). Taken together, 
dysfunction of the HTR1A or the HTR2B receptor might lead to 
abnormal serotonin release in the CNS.
Glutamate Pathway
Excitatory Amino Acid Transporter 1 (SLC1A3 or 
EAAT1)
Altered cortico-striatal-thalamo-cortical (CSTC) circuitry is 
believed to provide the neurobiological basis for TD (7, 87). 
Glutamate is the major excitatory neurotransmitter in CSTS 
circuitry. A missense mutation (E219D) in the glutamate trans-
porter gene (SLC1A3) was associated with TD in a case-control 
study (88). In the same study, cells transfected with the E219D 
mutant glutamate transporter gene exhibited increased glutamate 
uptake activity compared to cells transfected with the wild-type 
gene. The proposed mechanism for the increased glutamate 
uptake activity was elevated glutamate transporter expression 
at the plasma membrane due to the E219D mutation. However, 
whether TD might be associated with hypo- or hyper-glutamate 
activity is still controversial.
One of the five subtypes of glutamate transporters, EAAT1, is 
responsible for the reuptake of the excitatory neurotransmitter, 
l-Glutamate, from the synapses back into cells. Dysfunction of 
glutamate transporters may lead to imbalanced extracellular 
glutamate levels, further affecting downstream glutamate neu-
rotransmission or causing glutamate excitotoxicity to neurons 
(89, 90). EAAT1 is primarily expressed in glial cells. Regionally, 
EAAT1 proteins are found in neocortex, striatum, cerebellum, 
and spinal cord (91). Eaat1 knockout mice showed hyperactivity 
and reduced acoustic startle response compared with the wild-
type mice (92) but did not exhibit the altered prepulse inhibition 
behavior, which has been found in TD patients (93). No Eaat1 
gain-of-function mutant mice are available to test the “hypo-
glutamate activity” hypothesis in TD.
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Synaptic Signal Transduction and  
Cell-Adhesion Pathways
Neuroligin 4, X Linked (NLGN4 or NLGN4X)
Mutations in the neuroligin (NLGN) family members have been 
identified in patients with neuropsychiatric disorders such as 
ASD (94–97) and schizophrenia (98). A small deletion in the 
NLGN4 gene was detected in a mother and her two sons (99), 
one of whom was diagnosed with autism while the other was 
diagnosed with TD and ADHD. Their mother, who also carried 
the deletion, had a learning disability, depression, and anxiety. 
The deletion spanned exon 4, 5, and 6 of the NLGN4 gene, result-
ing in a truncated protein. No other known genes were affected 
by the deletion.
Neuroligins are cell adhesion molecules located on the plasma 
membrane of the pre-synaptic and post-synaptic neurons. By 
interacting with neurexins, another family of cell adhesion pro-
teins, NLGNs modulate proper signal transmission between pre-
synaptic and post-synaptic neurons (100).Reduced expression of 
NLGNs in cultured neurons or mice cause deficits in synaptic 
maturation and plasticity (101, 102). Nlgn4 knockout mice have 
been studied at both the behavioral and cellular levels. Because 
Nlgn4 gene disruptions had been associated with ASD, the Nlgn4 
knockout mice were tested for ASD-like behaviors. As expected, 
Nlgn4 knockout mice exhibited deficits in social interactions 
and reduced ultrasonic vocalizations compared to the wild-type 
mice (103). In another study, the Nlgn4 knockout mice displayed 
reduced neural network response upon stimulation in both excita-
tory and inhibitory circuits (104). More interestingly, the Nlgn4 
knockout mice also showed stereotypic repetitive behaviors and 
increased obsessive compulsive like behaviors (105), supporting 
the possibility that disruption of the NLGN4 gene might play a 
role in TD or related disorders.
Cadherin 2, Type1, N-Cadherin (CDH2)
Cadherin 2 (CDH2), also known as N-Cadherin, is another cell 
adhesion protein that has been associated with TD. CDH2 par-
ticipates in neuron–neuron communication and in synaptogen-
esis. In a recent study, exons of the CDH2 gene were sequenced 
in 160 OCD probands and 160 controls (106). Four variants in 
the CDH2 gene were identified in subjects with OCD or TD. 
Two mutations were of particular interest: the N706S and the 
N845S variants. N706S is a rare and novel mutation close to the 
predicted proteolytic cleavage site of the CDH2 protein while the 
N845S variant is located at the β-catenin interacting region. Both 
mutations reduced the CDH2 protein level by more than 50% 
in transfected HEK293 cells (106), suggesting possible adhesion 
deficits in cells.
Cadherin 2 is a calcium-dependent cell–cell adhesion glyco-
protein. CDH2 primarily mediates neurite outgrowth and axon 
guidance of neurons on myotubes (107) and on the surface of 
astrocytes (108, 109). The cytosolic domain of the CDH2 protein 
forms complexes with catenin proteins (110), and these com-
plexes regulate synaptogenesis in both pre- and post-synaptic 
neurons (111, 112). Additionally, the cleaved C-terminal domain 
of the CDH2 is a repressor of CBP/CREB-mediated transcrip-
tion whose target genes are critical in neural development and 
plasticity (113). The complete knockout of the Cdh2 gene is an 
embryonic lethal in mice whereas Cdh2 heterozygous null mice 
do not exhibit obvious morphological defects during development 
(114). Conditional knockout of the Cdh2 gene in the cerebral 
cortex of mice caused disrupted cortical structure (115). Thus far, 
behavioral analyses in the Cdh2+/− mice or Cdh2 conditional 
knockout mice have not been conducted.
Contactin-Associated Protein-Like 2 (CNTNAP2/
CASPR2)
Variants in the CNTNAP2 gene have been associated with ASD in 
several family based studies (116–119). Also, putative deleterious 
mutations were found in the CNTNAP2 gene in ASD patients 
(120). In one family, an insertion on chromosome 7p35–p36, 
disrupting intron 8 of the CNTNAP2 gene, was shared by a father 
and his two children, all three of whom were diagnosed with TD 
(121). However, a translocation disrupting intron 11 of CNTNAP2 
did not cause TD phenotypes in another three generation family 
(122).
CNTNAP2, a transmembrane protein, belongs to the neurexin 
superfamily and is highly expressed in neurons and localized to the 
axonal membrane of the juxtaparanodal region. The CNTNAP2 
protein interacts with clustered Shaker-type potassium channels 
and plays an important role in the axon-glia septate-like junc-
tion (123). It is required for normal action potential propagation 
along myelinated axons of the neurons (124), and it has been 
hypothesized that malfunctions of the CNTNAP2 protein leads 
to deficits of electric signal transduction between neurons (121, 
125, 126).
Behavioral assessments of Cntnap2 knockout mice led to 
stereotypic motor movements (127). Interestingly, a reduced 
number of GABAergic interneurons were reported in the 
striatum of the Cntnap2 knockout mice, which is consistent with 
previous post-mortem studies showing a reduction in the num-
ber of striatal GABAergic interneurons in TD patients (9, 21). 
Therefore, understanding the molecular mechanism of neuronal 
loss caused by disruption of CNTNAP2 may help to pinpoint 
biological pathways altered in TD.
Dipeptidyl-Peptidase 6
A heterozygous microdeletion at the first exon of the DPP6 gene 
was identified in a boy with TD as well as the boy’s father and 
paternal uncle both of whom were diagnosed with tic disorder 
and ADHD (128). The microdeletion led to decreased DPP6 
mRNA level in the boy’s blood cells. DPP6 has also been associ-
ated with other neuropsychiatric disorders such as ASD (95, 129) 
and schizophrenia (130).
Dipeptidyl-peptidase 6 (DPP6) is a transmembrane protein 
belonging to a family of serine proteases. However, DPP6 does 
not have protease activity (131). DPP6’s expression is enriched in 
the brain and different isoforms have different distributions in the 
brain. (132). DPP6 proteins interact with A-type voltage-gated 
potassium channels, specifically the Kv4 subunit (133, 134). The 
A-type potassium channels participate in the modulation of den-
dritic signal transmission (135, 136). Moreover, the A-type potas-
sium channel was reported to control the tonic dopamine release 
February 2016 | Volume 7 | Article 116
Sun et al. Functional Studies in Tourette’s Disorder
Frontiers in Psychiatry | www.frontiersin.org
by substantia nigra dopaminergic neurons (137). Even though 
DPP6 has no peptidase activity, it may have novel functions and 
play essential roles in Kv4 intracellular trafficking, membrane 
expression, and proper function of the A-type potassium channels 
(138). Dpp6 knockout mice show abnormal synaptogenesis (139), 
and knocking down the Dpp6 gene specifically in the mouse brain 
caused impaired learning and memory abilities (140).
Mitochondria Functions
Inner Mitochondrial Membrane Peptidase 2 Like
A familial translocation segregating with TD or tics (141) and a 
de novo duplication in a TD patient with other developmental and 
mental phenotypes implicated IMMP2L as a possible TD candi-
date gene (142). This was the first mitochondria-related gene in 
TD. Subsequently, a cryptic deletion eliminating exons 1–3 of the 
IMMP2L gene and 21 other genes was identified in a TD patient 
with learning and speech difficulties (143). Also, a case-control 
study of copy number variations reported intragenic deletions at 
the IMMP2L gene in seven TD patients (144). Among the seven, 
three deletions at intron 3 led to production of a shorter IMMP2L 
mRNA transcript due to alternative splicing. In the same study, 
the expression of both the short and the long transcripts was 
examined by reverse transcription PCR in 19 regions of the human 
brain. While the long transcript was ubiquitously expressed in all 
19 brain regions, the short transcript was selectively expressed at 
a lower level in only 10 brain regions, suggesting that the short 
transcript might have a more specific role in the human central 
nervous system (144).
The human inner mitochondrial membrane peptidase 2 like 
(IMMP2L) protein is one of the catalytic subunits of the inner 
mitochondrial membrane peptidase (IMP) complex (145, 146). 
The IMP complex participates in the cleavage of the inner mito-
chondrial membrane targeting signal sequence from its protein 
substrates, allowing maturation of the substrates. Loss of any 
subunit will cause the decomposition of the whole complex (147). 
Expression and function of the mammalian IMMP2L protein 
have been studied in animal models and human tissues. Immp2l 
knockout mice exhibit mitochondrial dysfunction, increased 
ischemic brain damage, and infertility (148, 149).The human 
IMMP2L mRNAs are ubiquitously expressed in various tissues 
except for adult liver and lungs. Unlike other TD associated genes, 
there is no enriched IMMP2L mRNA expression in the brain 
compared to other tissues (142). However, linking mitochondrial 
dysfunction to TD might lead to further speculation about the 
varied etiology of TD.
Mitochondrial Ribosomal Protein L3
Whole exome sequencing of a multiplex TD family showed three 
rare novel non-synonymous mutations in the MRPL3, DNAJC13, 
and the OFCC1 genes (150). The three variants were not found 
in controls or dbSNPs/1000 Genomes databases. However, a 
targeted-sequencing study of the same three variants in Han 
Chinese TD patients did not replicate these findings (151).
Mitochondrial ribosomal protein L3 (MRPL3) is a mito-
chondrial ribosome protein involved in mitochondrial protein 
translation (152). Compound heterozygous mutations in the 
MRPL3 gene were associated with mitochondrial respiratory 
chain deficiency in a pedigree of French origin (153), but no 
psychiatric diseases were reported.
Genes Associated with Other Diseases
DnaJ (Hsp40) Homolog, Subfamily C, Member 13 
(DNAJC13)
A missense variant (A2057S) in the DNAJC13 gene was found 
to segregate with TD or chronic tic disorder (CTD) in a mul-
tiplex pedigree (150). Subsequently, a novel missense mutation 
Asn855Ser in the DNAJC13 gene was found in a multi-generation 
family with PD and in an additional four other PD patients (154). 
Human DNAJC13 is a membrane-associated protein involved 
in endocytosis, specifically in the process of early endosome-
mediated membrane trafficking (155, 156). Knocking down 
the DNAJC13 gene in mammalian cells did not cause obvious 
dysfunction of endocytosis. However, introducing a C-terminus 
truncated mutant DNAJC13 protein into the cells did affect the 
normal distribution and formation of early endosomes (156). No 
DNAJC13 knockout animal model is available.
Orofacial Cleft 1 Candidate 1
After an initial study suggesting that the OFCC1 gene led to 
orofacial clefts (157), it was later linked to schizophrenia (158). 
Recently, a genome-wide association study (GWAS) of OCD 
found a significant association with OFCC1 (159). Sequence 
variants in OFCC1 have been found in patients with neurode-
velopmental or neuropsychiatric disorders: a missense mutation 
(R129G) segregating with TD and CTD in a multiplex family 
(150) and a non-sense and a missense mutation were found in a 
single autism family (160).
The function of the orofacial cleft 1 candidate 1 (OFCC1) pro-
tein is unclear but one study suggested that the OFCC1 protein 
was an interacting partner and methylation substrate of protein 
arginine methyltransferase 1 (161). However, Ofcc1 knockout 
mice did not show any behavioral abnormalities (158).
Hypocretin (Orexin) Receptor 2 (HCRTR2/OX2R)
The coding regions of the orexin-1/hypocretin-1 (OX1R) 
receptor gene, the orexin-2/hypocretin-2 (OX2R) gene, and the 
prepro-orexin gene were examined in patients with Excessive 
Daytime Sleepiness, TD, or ADHD and healthy controls (162). A 
C29T nucleotide change in the OX2R gene producing a Pro10Ser 
amino acid substitution was detected in only one TD patient with 
comorbid ADHD. The Pro10Ser variant reduces responsiveness 
of the Orexin2 receptor to its ligands, Orexin-A, and Orexin-B. 
The Orexin receptor 2 is a G protein-coupled receptor that 
participates the regulation of feeding and sleep-wakefulness in 
mammalian brains (163). Ox2r knockout mice do not show any 
tic-like behaviors (164).
FUNCTiONAL ANALYSeS OF GeNeS 
DiSRUPTeD iN TD
As indicated in the previous section, evidence for TD susceptibil-
ity genes exists. The mutations discussed were found in only a 
small number of individuals with TD, and replication remains 
elusive. This lack of replication may be due to the extreme locus 
February 2016 | Volume 7 | Article 117
Sun et al. Functional Studies in Tourette’s Disorder
Frontiers in Psychiatry | www.frontiersin.org
heterogeneity, similar to what has been found in ASD (165). 
What evidence beyond stronger statistical association might 
help establish their potential role in TD pathogenesis? Some of 
these genes are found within neurobiological pathways that are 
presumed to be disrupted in TD (e.g., neural signal transmission/
modulation) while others are found in novel pathways. Hence, 
the evidence that these genes are true susceptibility genes remains 
insufficient. Consequently, more convincing functional stud-
ies are needed to determine how variants in these genes could 
contribute to TD. In this next section, we review the in vitro and 
in vivo functional studies and techniques (beyond the knock out 
experiments referred to above) that will likely be useful to evaluate 
the consequences of mutations found in these presumptive TD 
susceptibility genes and for discovery of cellular and molecular 
phenotypes in disease.
Transgenic Mammalian Cell Lines
Functional studies using neuronal cells from individuals with 
TD can provide insights into the molecular basis of TD and 
potentially help to clarify the biological pathways altered in TD. 
However, one of the difficulties is the inability to obtain relevant 
biomaterials (e.g., neurons or neural stem cells) from affected 
individuals. Since TD is not a lethal disorder, there is very limited 
access to neural tissue from individuals with TD, particularly 
from individuals with a known causal variant.
Transgenic human non-neuronal cell lines have been used 
to characterize the cellular and molecular phenotypes resulting 
from specific mutations. Typically, plasmids carrying a wild 
type or a mutant gene of interest are delivered into the cell lines. 
Once the protein products of the transgene are expressed in the 
cells, assays are developed to evaluate the functional conse-
quences of the mutant proteins. For example, in the CDH2 gene, 
both the wild type and mutant CDH2 genes were cloned into 
expression plasmids and subsequently delivered into human 
embryonic kidney (HEK293) cells and reduced expression of 
mutant CDH2 proteins was reported (106). While easily done, 
functional studies in non-neuronal cell lines are suboptimal for 
a variety of reasons. During transgenesis, the gene of interest is 
often transiently overexpressed or is controlled by a conditional 
and/or inducible gene expression system (166). Therefore, the 
level of transgene expression might not faithfully represent the 
endogenous gene expression level. Also, the expression levels 
of many genes are tissue-specific (167). This is particularly 
relevant for genes with multiple transcript isoforms where the 
isoform expression pattern in transgenic cell lines may not 
be comparable to patterns in neurons. Furthermore, because 
transgenic cells would not be expected to have the same gene 
expression profile as neurons, they may not provide relevant 
cellular environment for the transgene to execute its genuine 
neuronal function(s). Neuronal samples from TD patients are 
therefore preferred for in vitro functional studies but these are 
very difficult if not impossible to obtain. A recent technological 
advance, induced pluripotent stem cells (iPSCs), now makes 
functional studies of neuronal samples with a known causal 
variant possible.
induced Pluripotent Stem Cells
Use of iPSC-Derived Neuronal Cells to Model 
Neuropsychiatric and Neurodevelopmental 
Disorders
The relatively new reprograming technique that converts human 
somatic cells into iPSCs allows researchers to model diseases 
in  vitro using patient-derived cells. Since the first generation 
of iPSCs from mouse fibroblasts (168), the ability to produce 
differentiated cells from iPSCs has been intensively studied 
and improved. Recently, iPSC neuronal differentiation has 
become routine (169). Generating patient-specific neurons 
carrying mutations in disease candidate genes is invaluable for 
researchers who wish to study the cell-autonomous effects of 
mutations and to understand the cellular basis of neurological 
and neuropsychiatric disorders. To date, no study using iPSC-
derived neurons to model TD has been published. However, 
mutations associated with other neuropsychiatric disorders have 
been studied in iPSC-derived neurons, and cellular abnormalities 
have been demonstrated (170–174). For example, Rett syndrome 
is a neurodevelopmental disorder occurring mainly in females 
characterized by mental retardation. Loss-of-function muta-
tions in the methyl-CpG binding protein 2 (MeCP2) gene were 
reported in the majority of Rett Syndrome cases (170). Therefore, 
neurons with functional null mutation in the MeCP2 gene were 
generated from the iPSCs of an individual with Rett Syndrome. 
In culture, the neurons showed smaller soma size (171). Similarly, 
iPSC-derived neurons have been used to understand ASD. In 
an individual with ASD, a balanced translocation spanning the 
transient receptor potential 6 channel (TRPC6) gene was identi-
fied. Neurons derived from the iPSCs exhibited decreased TRPC6 
expression, altered morphology and reduced Ca2+ influx (172). In 
schizophrenia, the DISC1 gene has been considered an important 
risk factor (175) and in iPSC-derived DISC1 mutant neurons, 
pre-synaptic vesicle release was impaired (173).
Unfortunately, in  vitro neural differentiation from iPSCs 
yields mixed populations of neurons rather than a homogenous 
population. For diseases with clear neuropathology, pure cultures 
of the specific neuron types involved in the disorder are preferred 
in order to recapitulate disease-related cellular phenotypes. For 
instance, PD is characterized by loss of substantia nigra dopa-
mine neurons (176). Cultures containing a high percentage of 
dopaminergic neurons were generated from PD patients who 
carry monogenic mutations (177–180), and defects in cel-
lular functions such as autophagy, mitophagy, oxidative stress 
response, and dopamine release were found in these neurons. In 
patients with amyotrophic lateral sclerosis (ALS), motor neurons 
degenerate. Therefore, motor neurons were derived from iPSCs 
of ALS patients carrying known casual mutations (174, 181). 
As hypothesized, the mutant motor neurons exhibited neurite 
degeneration (181).
Use of Single-Cell Analysis to Overcome Culture 
Heterogeneity
One method to overcome cell culture heterogeneity is to analyze 
single cells, all of the same type. Looking at the transcriptome 
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of single cells using microarray or RNA-seq analysis holds prom-
ise of detecting gene dysregulation in particular populations of 
neurons, which might not be identified by analyzing heterogene-
ous mixtures of cells. For instance, single-cell gene expression 
analysis of iPSC-derived dopamine neurons from PD patients 
with a LRKK2 mutation unveiled dysregulation of oxidative 
stress genes in mutant dopamine neurons (182). In another study, 
neurons were generated from the iPSCs of Timothy Syndrome 
patients with a mutation in the CACNA1C gene. Single cells were 
taken from the culture containing mixed neuron populations, 
and gene expression was analyzed by microarray. As a result, 
the distribution of neuron subtypes was altered in the Timothy 
Syndrome neuronal culture compared to the control cells (183). 
Compared to microarray, RNA-seq is gaining greater popularity 
for analyzing the transcriptome of single cells due to its ability to 
unbiasedly detect any transcript in cells within a broader dynamic 
range of expression. Generally, there are four important steps to 
achieve single-cell RNA-seq: (1) single-cell isolation, (2) RNA 
capture, (3) cDNA synthesis and, (4) next generation sequenc-
ing. The microfluidic system is becoming popular for single-cell 
RNA-seq because it can isolate single cells, lyse the cells, purify 
RNA, synthesize cDNA or even conduct gene expression analysis 
all in one run (184, 185).
Use of iPSC-Derived Cerebral Organoids to Model 
Neuropsychiatric and Neurodevelopmental Disorders
In contrast to PD or ALS, the neuropathology of many neurode-
velopmental and neuropsychiatric disorders, such as TD or ASD, 
is unclear or is heterogeneous (18). As described above, muta-
tions associated with TD indicate dysregulations of various neu-
rotransmitter pathways or of neural circuits involving multiple 
brain regions. Hence, studying specific type of neurons may not 
help to explain the pathogenesis of TD. The recently developed 
“cerebral organoid” cellular system enables the differentiation of 
iPSCs into a three-dimensional miniature organ in a bioreactor, 
with minimum external interferences (186). Such self-organized 
spherical structures resemble the human brain at very early 
stages of development. In comparison to monolayer neuronal 
cultures, the cerebral organoids contain more diverse neuronal 
populations that define distinct brain regions. Also, within the 
cerebral organoid, neuronal migration and human-specific brain 
structures (e.g., the outer subventricular zone) were observed 
(187). Therefore, the cerebral organoid has been used to model 
neurodevelopmental diseases. For microcephaly, premature neu-
ral differentiation was recapitulated in organoids derived from 
microcephaly patients’ iPSCs (187). In cases of idiopathic ASD, 
overproduction of GABAergic inhibitory neurons in patient-
derived cerebral organoids was reported (188). At the molecular 
level, the cellular phenotype was explained by overexpression of 
the transcription factor FOXG1. However, use of cerebral orga-
noids to model neurodevelopmental diseases has limitations. The 
various “brain regions” in the organoids are fairly disorganized. 
Therefore, the cerebral organoid would not be suitable to study 
neural circuits. Furthermore, neuronal cells within the organoids 
are mostly neural progenitor cells, and their differentiation is 
restricted by limited growth of the organoids, which in turn is 
probably due to the lack of internal nutrient and oxygen supply. 
More importantly, each organoid is “unique” because the self-
organization process is random and is not controlled by external 
factors. This “uniqueness” will generate variation among orga-
noids, which may mask phenotypic differences between normal 
and patient-derived cells.
Use of Genome Editing to Generate Isogenic Control 
iPSC Lines
One challenge in identifying the phenotypic effects of a given 
mutation in iPSC-derived neurons is finding an appropriate 
control sample. While age, gender, and ethnicity-matched con-
trol samples with the wild-type allele are typically available, they 
are not matched for all of the other common genomic variants. 
Failure to control for such variability in genetic background 
can lead to spurious results. The recent technological advance 
of highly specific genome editing now allows the production of 
more comparable isogenic controls for functional studies. Several 
genome editing systems, such as zinc finger nuclease (189, 190), 
TALEN, and CRISPR-Cas9 (191, 192), are able to reverse the 
mutation to wild type at one genomic locus at a time in iPSCs. 
Comparing neuronal cells generated from mutant iPSCs and 
their edited, isogenic control neuronal cells with the mutation 
removed allows identification of molecular and cellular changes 
that are due only to the mutation (180). However, “off target” 
mutations at unrelated loci inadvertently introduced by editing 
remain a potentially important technological hurdle (193).
Gene expression and Gene Network 
Analyses
The major goal of genomic sequencing of patients with neurode-
velopmental and neuropsychiatric disorders is to identify disease-
associated mutations. Once such genes are found, systematic 
approaches including genome-wide gene expression analysis and 
gene network analyses can be used to implicate common biologi-
cal pathways altered in patients with different mutant genes.
Gene Expression Analysis
Gene expression analysis, primarily through the RNA-seq 
approach, aims to quantify transcript level of target genes or 
of the whole transcriptome in biological samples from patients 
and healthy controls to identify genes dysregulated in human 
diseases (194). For neurodevelopmental disorders, post-mortem 
brain samples are often used for the transcriptomic analyses. 
The first transcriptomic analysis of TD patients’ post-mortem 
striatum samples revealed that interneuron disruption might 
be involved in the pathophysiology of TD (34). However, to 
evaluate particular mutations, post-mortem samples meeting 
specific research criteria are usually difficult or virtually impos-
sible to obtain. With the emergence of somatic cell reprograming 
techniques, iPSC-derived neurons with and without a putative 
disease-causing mutation can be produced in  vitro (195). The 
transcriptomes of these iPSC-derived neurons can be compared 
by microarray or RNA sequencing (RNA-seq) (172, 173). To 
further dissect the cellular phenotype at single neuron level and 
to detect abnormalities only shown in particular populations of 
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neurons, single-cell transcriptome analysis can also be performed 
(182, 183). Multiple bioinformatic tools have been developed for 
RNA-seq data to detect differentially expressed genes (DEGs) 
from distinct cell types or under different experimental condi-
tions (196–198). Among these RNA-seq analysis methods, 
none outperforms the others in all aspects. Selecting an optimal 
method for a study requires an understanding of the benefits 
and limitations of each method as well as the parameters of the 
study (196). Once the DEGs between experimental conditions 
are determined, gene and pathway annotation tools, gene and 
protein expression and interaction databases can help to explore 
the gene pathways underlying the disorder. Gene and pathway 
annotations tools such as IPA1, KEGG (199, 200), DAVID (201, 
202), ConsensusPathDB (203) report biological pathways in 
which DEGs are enriched or reduced and take these into account 
to predict how these pathways might be affected. However, the 
data from which these tools were constructed come from non-
neuronal samples which could lead to associations not found in 
neuronal tissues or failure to detect neuronal associations (204). 
In order to annotate neuronal gene expression in a temporal 
and spatial manner, human brain gene expression databases, for 
example, the Allen Human Brain Atlas (205), BrainSpan (206), 
GTEx (207) were built using microarray and RNA-seq data 
from post-mortem brain samples. Mapping DEGs identified in 
neuronal samples of patients with neurodevelopmental disorders 
to human brain gene expression databases revealed specific brain 
regions and neural developmental stages that were affected (34, 
208). A more detailed human brain gene expression atlas that 
annotates gene expression at single cell level has been initiated 
by a group in Stanford University (209). Single-cell RNA-seq was 
used to analyze neurons from human adult and fetal cerebral cor-
tex and it identified more diverse populations of neurons within 
the cortical region (209). Constructing a comprehensive human 
brain gene expression database at single neuron resolution is quite 
challenging due to limited access to healthy human brain samples 
and the high cost of single-cell RNA-seq. Therefore, collaborative 
work with standardized experimental protocols is required.
Gene Network Analysis
Differential gene expression from transcriptome analysis is 
sample-dependent and tissue-specific. In order to explore the 
etiology of complex neurodevelopmental disorders such as TD, 
disease-associated genes can be mapped to gene networks to visu-
alize relationships between disease candidate genes and, further, 
to pinpoint annotated or novel pathways. The gene networks can 
be gene co-expression networks (205, 206), gene regulatory net-
works2, protein–protein interaction networks (210) or networks 
constructed with combined criteria (203, 211). For example, 
in ASD, disease-associated genes have been evaluated using 
spatiotemporal gene co-expression networks constructed from 
BrainSpan (206) and were found to be enriched in sub-networks 
that represent specific brain regions and time periods during 
human brain development (212). Furthermore, ASD-associated 
1 www.qiagen.com/ingenuity
2 http://www.braineac.org/
mutations identified by previous genetic studies were mapped to 
a “background network” which scores each pair of human genes 
based on very comprehensive information about every known 
human gene (211). Cell types and brain areas affected in ASD 
were implicated (213). With a growing number of mutations 
associated with TD, the same approaches could be utilized in TD.
Animal Models
Another approach to the study of the functional effects of a specific 
mutation in a gene is to use animal models. Most often, a putative 
disease gene is knocked out or modified in the animal model. 
Then, the mutant and wild type animals from the same genetic 
background are compared. (Some such animal knock-out studies 
of putative TD genes have been described above). Conventional 
animal models are designed to study a small number of genes, 
usually one or two genes at a time. If, however, TD is caused by 
the combined effect of multiple variant genes, multi-transgenic 
animals, whose genomes are modified at multiple loci, would be 
required. Although more challenging, generation of such multi-
transgenic animals can be achieved by genome editing as well. 
(214, 215).
In order to model TD in animals, the following criteria should 
be met: (1) the gene to be studied is strongly associated with the 
disease; (2) the gene and the neurological component phenotypes 
involved in TD are relatively well conserved between humans and 
the animal; (3) the gene is thought to have similar functions in 
both humans and the model animals; and (4) the disease pheno-
type can be experimentally characterized in the model animals 
by biochemical and/or behavioral approaches (216). One mouse 
model in TD that meets these criteria is HDC. As indicated 
previously, a rare dominant non-sense mutation W317X in 
HDC cosegregated with all TD individuals in a two generation 
pedigree. (25). Subsequently, a study using HDC knockout mice 
demonstrated behavioral and molecular abnormalities caused 
by the loss of the HDC activity in the brain (28). The knockout 
and heterozygous mice showed tic-like stereotypic movements 
after psychostimulant administration. Also, the striatal dopa-
minergic pathway was dysregulated due to the HDC deficiency. 
Specifically, the dysregulation of dopamine receptors in the basal 
ganglia region of the HDC knockout and heterozygous mice 
recapitulated the dysregulation of the same types of dopamine 
receptors in TD patients carrying the W317X mutation.
SUMMARY AND FUTURe DiReCTiONS
Tourette’s disorder is likely caused by a complex multigenic 
inheritance pattern that includes locus and allelic heterogeneity 
of both common and rare variants that interact with environmen-
tal factors (14, 217, 218). Despite long-standing interest in the 
genetic contribution to TD, the overall genetic architecture of TD 
remains elusive. Some of the genes identified as causal of TD are 
involved in neurotransmitter pathways presumed to be altered 
in TD, while others are novel. In this respect, the genetics of TD 
may resemble that of other complex neuropsychiatric disorders. 
Indeed, there is evidence of some overlap with subsets of similar 
genes involved in multiple disorders. Furthermore, there also 
appears to be an increased rate of comorbidity between some such 
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disorders, such as TD and ASD (27, 219). It may also be that cur-
rent DSM-based psychiatric nosology does not sufficiently “carve 
nature at its joints,” and that other classification schemes, such 
as Research Domain Criteria (RDoC)(220–224), might reveal 
etiologically more coherent groupings of disorders or patients.
International consortiums including the Tourette International 
Collaborative Genetics (TIC Genetics), the Tourette Syndrome 
Association International Consortium for Genetics (TSAICG), 
the European Multicenter Tics in Children Studies (EMTICS), the 
European Society for the Study of Tourette Syndrome (ESSTS), 
the Tourette Syndrome Genetics The Southern and Eastern 
Europe initiative (TSGeneSEE), and sharing repositories (New 
Jersey Center for Tourette Syndrome Repository) (225, 226) have 
initiated large collaborations to collect many patient and family 
samples in an effort to understand the genetics of TD. Continued 
efforts in gene discovery from large open-access repositories are 
needed to find additional risk variants.
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